NO319313B1 - Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet - Google Patents

Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet Download PDF

Info

Publication number: NO319313B1
Authority: NO; Norway
Prior art keywords: nmda receptor; opioid antagonist; receptor complex; treatment; complex modulator
Prior art date: 1998-03-26

Application number

NO20004788A

Other languages

English (en)

Norwegian (no)

Other versions

NO20004788L (no

NO20004788D0 (no

Inventor

Philippe Durbin

Yves Bonhomme

Martine Daoust

Original Assignee

Lipha

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-26

Filing date

2000-09-25

Publication date

2005-07-11

2000-09-25 Application filed by Lipha filed Critical Lipha

2000-09-25 Publication of NO20004788D0 publication Critical patent/NO20004788D0/no

2000-11-24 Publication of NO20004788L publication Critical patent/NO20004788L/no

2005-07-11 Publication of NO319313B1 publication Critical patent/NO319313B1/no

Links

102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title claims abstract description 25
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title claims abstract description 25
238000011282 treatment Methods 0.000 title claims abstract description 19
239000003401 opiate antagonist Substances 0.000 title claims abstract description 18
208000007848 Alcoholism Diseases 0.000 title claims abstract description 10
201000007930 alcohol dependence Diseases 0.000 title claims abstract description 7
239000011885 synergistic combination Substances 0.000 title claims description 4
229960003086 naltrexone Drugs 0.000 claims description 15
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 15
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical group NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 12
AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical group CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 10
229960004047 acamprosate Drugs 0.000 claims description 10
239000000825 pharmaceutical preparation Substances 0.000 claims description 7
229940063673 spermidine Drugs 0.000 claims description 6
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 4
229960004127 naloxone Drugs 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
230000002195 synergetic effect Effects 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 70
206010013663 drug dependence Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
241000700159 Rattus Species 0.000 description 11
230000000694 effects Effects 0.000 description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
239000002775 capsule Substances 0.000 description 7
230000037396 body weight Effects 0.000 description 6
229920000768 polyamine Polymers 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000004471 Glycine Substances 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000035622 drinking Effects 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000000034 method Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
108091006146 Channels Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000027455 binding Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001722 neurochemical effect Effects 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000002747 voluntary effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical class NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
101800005049 Beta-endorphin Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
229940127337 Glycine Antagonists Drugs 0.000 description 1
206010021033 Hypomenorrhoea Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
241000238370 Sepia Species 0.000 description 1
VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
229950004794 dizocilpine Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229950005455 eliprodil Drugs 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000009540 excitatory neurotransmission Effects 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
231100000063 excitotoxicity Toxicity 0.000 description 1
238000013265 extended release Methods 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 1
AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 1
229960003998 ifenprodil Drugs 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000013289 male long evans rat Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000009120 supportive therapy Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20004788A 1998-03-26 2000-09-25 Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet NO319313B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98400723A EP0945133A1 (de)	1998-03-26	1998-03-26	Pharmazeutische Zusammensetzung zur Behandlung von Alkohol- oder Drogenabhängigkeit, die Opioid Antagonisten mit NMDA-Rezeptorkomplex-Modulatoren enthält
PCT/EP1999/002337 WO1999048500A1 (en)	1998-03-26	1999-03-26	Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (3)

Publication Number	Publication Date
NO20004788D0 NO20004788D0 (no)	2000-09-25
NO20004788L NO20004788L (no)	2000-11-24
NO319313B1 true NO319313B1 (no)	2005-07-11

Family

ID=8235311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20004788A NO319313B1 (no)	1998-03-26	2000-09-25	Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet

Country Status (17)

Country	Link
US (1)	US6512009B1 (de)
EP (2)	EP0945133A1 (de)
KR (1)	KR20010034678A (de)
AT (1)	ATE230993T1 (de)
AU (1)	AU758569B2 (de)
BR (1)	BR9909138A (de)
CA (1)	CA2325739C (de)
CZ (1)	CZ296367B6 (de)
DE (1)	DE69904922T2 (de)
DK (1)	DK1063995T3 (de)
ES (1)	ES2190205T3 (de)
HU (1)	HU226555B1 (de)
NO (1)	NO319313B1 (de)
PL (1)	PL193241B1 (de)
RU (1)	RU2226107C2 (de)
SK (1)	SK284623B6 (de)
WO (1)	WO1999048500A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8052982B2 (en)	1998-07-20	2011-11-08	Peptech Animal Health Pty Limited	Bioimplant formulation comprising lecithin and stearin
CA2336879C (en) *	1998-07-20	2010-06-01	Peptech Limited	Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
WO2001052851A1 (en) *	2000-01-22	2001-07-26	Albert Shulman	Methods for the treatment of substance abuse
EP1262196A3 (de) *	2001-05-23	2002-12-18	Pfizer Products Inc.	Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
DE10129265A1 (de) *	2001-06-18	2003-01-02	Hf Arzneimittelforsch Gmbh	Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) *	2001-09-24	2004-09-16	Garbil Pharma Investigacion Chile Ltda	Aminas como agentes anti-alcoholismo.
CA2487577C (en)	2002-05-31	2014-11-18	Titan Pharmaceuticals, Inc.	Implantable polymeric device for sustained release of buprenorphine
ATE482695T1 (de)	2002-12-13	2010-10-15	Durect Corp	Orale darreichungsform mit flüssigen hochviskosen trägersystemen
EP1572164A2 (de) *	2002-12-18	2005-09-14	Pain Therapeutics, Inc.	Orale dosierungsformen enthaltend medikamentenkerne mit kontrollierter freisetzung und gelatinkapselbeschichtungen mit sofortfreisetzung
SI1610791T1 (sl) *	2003-03-31	2011-05-31	Titan Pharmaceuticals Inc	Implantibilna polimerna naprava za zadrĹľano sproĹˇÄŤanje dopaminskega agonista
MXPA05012768A (es) *	2003-05-30	2006-02-22	Titan Pharmaceuticals Inc	Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
US20070099947A1 (en) *	2005-11-03	2007-05-03	Alkermes, Inc.	Methods and compositions for the treatment of brain reward system disorders by combination therapy
JP2010513569A (ja) *	2006-12-19	2010-04-30	ユニバーシティオブバージニアパテントファウンデーション	アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
JP2011506319A (ja) *	2007-12-06	2011-03-03	デュレクトコーポレーション	疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
MX2010009509A (es)	2008-02-28	2010-11-30	Univ Virginia	Gen transportador de serotonina y tratamiento de alcoholismo.
US20100260844A1 (en)	2008-11-03	2010-10-14	Scicinski Jan J	Oral pharmaceutical dosage forms
EA024450B1 (ru)	2010-07-02	2016-09-30	Юниверсити Оф Вирджиния Пэтент Фаундейшн	Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости
EP2751137A4 (de)	2011-09-09	2015-06-03	Univ Virginia Patent Found	Molekularer genetischer ansatz zur behandlung und diagnose von alkohol- und drogenabhängigkeit
RU2476209C1 (ru) *	2012-02-29	2013-02-27	Станислав Анатольевич Кедик	Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
AU2014233453A1 (en)	2013-03-15	2015-10-01	Durect Corporation	Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) *	2013-05-10	2013-06-19	Dalgleish Angus	Therapeutic
US12274794B2 (en)	2016-07-06	2025-04-15	Orient Pharma Co., Ltd.	Oral dosage form with drug composition, barrier layer and drug layer
WO2023023038A1 (en) *	2021-08-17	2023-02-23	Yale University	Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4882335A (en) *	1988-06-13	1989-11-21	Alko Limited	Method for treating alcohol-drinking response
JPH11505547A (ja) *	1996-03-13	1999-05-21	エールユニバーシティ	ナルトレキソン及び関連化合物を用いる禁煙処置

1998
- 1998-03-26 EP EP98400723A patent/EP0945133A1/de not_active Withdrawn
1999
- 1999-03-26 CA CA002325739A patent/CA2325739C/en not_active Expired - Fee Related
- 1999-03-26 CZ CZ20003525A patent/CZ296367B6/cs not_active IP Right Cessation
- 1999-03-26 EP EP99916907A patent/EP1063995B1/de not_active Expired - Lifetime
- 1999-03-26 PL PL343069A patent/PL193241B1/pl not_active IP Right Cessation
- 1999-03-26 DE DE69904922T patent/DE69904922T2/de not_active Expired - Lifetime
- 1999-03-26 AT AT99916907T patent/ATE230993T1/de active
- 1999-03-26 US US09/647,091 patent/US6512009B1/en not_active Expired - Lifetime
- 1999-03-26 KR KR1020007010649A patent/KR20010034678A/ko not_active Ceased
- 1999-03-26 WO PCT/EP1999/002337 patent/WO1999048500A1/en not_active Ceased
- 1999-03-26 SK SK1428-2000A patent/SK284623B6/sk not_active IP Right Cessation
- 1999-03-26 DK DK99916907T patent/DK1063995T3/da active
- 1999-03-26 RU RU2000126790/15A patent/RU2226107C2/ru not_active IP Right Cessation
- 1999-03-26 HU HU0101546A patent/HU226555B1/hu not_active IP Right Cessation
- 1999-03-26 ES ES99916907T patent/ES2190205T3/es not_active Expired - Lifetime
- 1999-03-26 BR BR9909138-0A patent/BR9909138A/pt not_active IP Right Cessation
- 1999-03-26 AU AU35226/99A patent/AU758569B2/en not_active Ceased
2000
- 2000-09-25 NO NO20004788A patent/NO319313B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2325739C (en)	2007-05-15
US6512009B1 (en)	2003-01-28
AU3522699A (en)	1999-10-18
BR9909138A (pt)	2000-12-05
DE69904922D1 (de)	2003-02-20
EP1063995A1 (de)	2001-01-03
HK1032542A1 (en)	2001-07-27
CA2325739A1 (en)	1999-09-30
SK14282000A3 (sk)	2001-05-10
HU226555B1 (en)	2009-03-30
DE69904922T2 (de)	2004-01-08
DK1063995T3 (da)	2003-03-10
HUP0101546A2 (hu)	2001-09-28
RU2226107C2 (ru)	2004-03-27
SK284623B6 (sk)	2005-08-04
NO20004788L (no)	2000-11-24
ATE230993T1 (de)	2003-02-15
PL343069A1 (en)	2001-07-30
ES2190205T3 (es)	2003-07-16
EP1063995B1 (de)	2003-01-15
PL193241B1 (pl)	2007-01-31
HUP0101546A3 (en)	2002-10-28
WO1999048500A1 (en)	1999-09-30
CZ296367B6 (cs)	2006-02-15
AU758569B2 (en)	2003-03-27
NO20004788D0 (no)	2000-09-25
EP0945133A1 (de)	1999-09-29
KR20010034678A (ko)	2001-04-25
CZ20003525A3 (cs)	2001-04-11

Legal Events

Date	Code	Title	Description
2014-11-03	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO319313B1 (no)	2005-07-11	Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet
WO2007005716A2 (en)	2007-01-11	Methods of treatment and compositions for use thereof
EP0942752A1 (de)	1999-09-22	Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathische schmerzen
NO20023482L (no)	2002-09-19	Fremgangsmåte for behandling av stoffmisbruk
JPH10505087A (ja)	1998-05-19	非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
ZA200700395B (en)	2008-04-30	Novel formulation for L-tryptophane comprising carbidopa/benserazide
AU2019381269B2 (en)	2025-03-06	Methods of using a phenoxypropylamine compound to treat pain
EP3060214A2 (de)	2016-08-31	Kombination aus zns-stimulans und opioid-rezeptorantagonist als nicht süchtig machende, nicht aversive und synergistische behandlung von adipositas
JP2019535758A (ja)	2019-12-12	リドカイン無効状態および低カリウム血症状態の治療のための療法
JP2024180674A (ja)	2024-12-26	薬物依存またはアルコール依存を処置するための方法
Kamei et al.	1994	Antinociceptive effect of L-arginine in diabetic mice
MXPA00009257A (en)	2002-03-26	Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
HK1032542B (en)	2003-07-25	Combination for the treatment of alcohol dependence containing an opioid antagonist and a nmda receptor complex modulator
RS20050738A (sr)	2008-04-04	Farmaceutska kombinacija za lečenje spastičnosti i/ili bola
RU2823100C2 (ru)	2024-07-18	Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения
CA2535811A1 (en)	2005-03-03	A pharmaceutical composition for the prevention and treatment of addiction in a mammal
Vadivelu et al.	2004	Buprenorphine pharmacology and clinical applications
WO2006130471A1 (en)	2006-12-07	The use delta opioid receptor agonists and/or inverse agonists to inhibit the consumption of substances of abuse
WO2025198489A1 (ru)	2025-09-25	Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения
CA2523331A1 (en)	2004-11-11	Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
HK40014066A (en)	2020-08-14	Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions